Soft Tissue Sarcoma Differences: Therapeutic Implications Soft Tissue Sarcoma Differences: Therapeutic Implications
Differences in the immunologic profiles of soft tissue sarcoma subtypes could have implications for treatment with immune checkpoint inhibitors, researchers report.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - May 4, 2017 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Development Program Can Support Approval, No New Studies Requested
NDA Submission by CytRx Being Prepared
Conference Call on April 19, 2017 at 8:30 AM EDT/ 5:30 AM PDT
LOS ANGELES, April 19, 2017 -- (Healthcare Sales & Marketing Network) -- CytRx... Biopharmaceuticals, Oncology, FDA CytRx, aldoxorubicin, soft tissue sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2017 Category: Pharmaceuticals Source Type: news
Saving Arms and Legs in Advanced Soft Tissue Sarcomas Saving Arms and Legs in Advanced Soft Tissue Sarcomas
In patients with soft tissue sarcoma facing amputation of an arm or a leg, regional chemotherapy with isolated limb infusion treats local disease without affecting survival.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 22, 2017 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news
A 5-Question Quiz on Sarcoma
Are you up to date on adverse prognostic factors for Ewing sarcoma? Do you know the latest drug approved for metastatic soft-tissue sarcoma? Test your knowledge on sarcoma in our latest quiz. (Source: CancerNetwork)
Source: CancerNetwork - February 5, 2017 Category: Cancer & Oncology Authors: Debra Hughes Tags: Quiz Source Type: news
Common heart drug repurposed to treat rare cancer in Europe
A drug that's commonly used to treat high blood pressure is being repurposed for a rare tissue cancer in Europe. The medication, named propranolol, was recently granted Orphan Drug Designation by the European Commission (EC). The designation signifies that the EC supports the use of a drug to treat patients because of its significant benefit to those living with a rare disease - in this case, soft tissue sarcoma. (Source: World Pharma News)
Source: World Pharma News - January 17, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New Cancer Drug Approvals From 2016
Chemotherapy is one of the most powerful tools we have to treat cancer, and research continues to find new chemotherapy drugs as well as new uses for existing ones. At the same time, newer types of drugs are continually being developed that work in different ways to attack cancer cells.They include targeted therapy, which aims to more precisely identify cancer cells while doing less damage to normal cells, and immunotherapy, which uses the body’s own immune system to help find and destroy cancer.Before any new drug can be sold in the United States, it has to go through an approval process by the Food and Drug Adminis...
Source: American Cancer Society :: News and Features - December 26, 2016 Category: Cancer & Oncology Tags: Advanced Cancer Source Type: news
Combo of cancer drugs shows promise against some tumors
HealthDay News Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 2, 2016 Category: Consumer Health News Source Type: news
Drug Combo Shows Promise Against Some Soft Tissue Tumors
FRIDAY, Dec. 2, 2016 -- Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates.
These cancers of soft tissues such as fat, muscles, blood vessels, tendons and ligaments are rare, but... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 2, 2016 Category: Journals (General) Source Type: news
Advanced soft tissue sarcomas respond to a combination of a new and an existing anti-cancer drug
Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 2, 2016 Category: Science Source Type: news
Advanced soft tissue sarcomas respond to new drug GDC-0575 combined with gemcitabine
(ECCO-the European CanCer Organisation) Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. Professor Antoine Italiano told the 28th EORTC-NCI-AACR Symposium that combining GDC-0575 with gemcitabine, a cancer-killing drug that is already used for treating sarcomas, proved remarkably effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2016 Category: Cancer & Oncology Source Type: news
Eli Lilly secures conditional marketing authorisation for olaratumab injection with doxorubicin
The European Commission (EC) has granted conditional marketing authorisation for Eli Lilly and Company ’s (LLY) olaratumab injection of 10mg/ml in combination with doxorubicin, to treat adults with advanced soft tissue sarcoma (STS) who are not suited… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 14, 2016 Category: Pharmaceuticals Source Type: news
Regorafenib Improves PFS in Non-Adipocytic Soft-Tissue Sarcoma
A phase II trial found that the multikinase inhibitor regorafenib has clinical activity and offers improved progression-free survival in certain types of advanced soft-tissue sarcoma. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news
PharmaMar shows new clinical data on Yondelis ® and lurbinectedin at ESMO 2016
(Pharmamar) During this congress, PharmaMar will inform in an oral session the results of its Phase II clinical trial with lurbinectedin in patients with BRCA 1/2 metastatic breast cancer.A prospective randomized phase III comparing trabectedin versus the best supportive care in patients with pretreated advanced soft tissue sarcoma(T-SAR trial) will be presented in an oral session by the French Sarcoma Group. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 5, 2016 Category: Global & Universal Source Type: news
Adding Palifosfamide Fails to Improve Survival in Metastatic Sarcoma
The addition of palifosfamide to doxorubicin failed to improve survival in a phase III trial of patients with metastatic soft-tissue sarcoma. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news
EU Panel Likes Breast Cancer Drug, Two Others EU Panel Likes Breast Cancer Drug, Two Others
Drugs for metastatic breast cancer, soft tissue sarcoma, and multiple myeloma all got a recommendation for approval.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
